<DOC>
	<DOCNO>NCT02465489</DOCNO>
	<brief_summary>The purpose study look pharmacokinetics new formulation deferiprone ( deferiprone extend release tablet ) feed fast condition .</brief_summary>
	<brief_title>Comparison Deferiprone Extended Release Tablets Ferriprox Immediate Release Tablets Healthy Volunteers</brief_title>
	<detailed_description>This single-center , open-label , randomize , 5-period , 5-sequence study pharmacokinetics new formulation deferiprone , extend release tablet , twenty healthy volunteer . In study period , blood sample pharmacokinetics assessment collect pre-dose 24 hour post-dose . Safety assess throughout study .</detailed_description>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>1 . Male female age â‰¥18 &lt; 50 year 2 . A female volunteer childbearing potential must agree use accepted contraceptive regimen least 28 day prior first administration study drug least 30 day last dose study drug 3 . A sexually active male must agree and/or female partner use medically acceptable method contraception throughout study least 30 day follow drug administration 4 . Body mass index ( BMI ) great equal 18.5 kg/m^2 30.0 kg/m^2 5 . Body weight least 60 kg 6 . Non ex smoker 7 . Clinical laboratory value within laboratory 's state normal range ; within range , abnormal value must without clinical significance 8 . Have clinically significant disease capture medical history , evidence clinically significant finding physical examination and/or clinical laboratory evaluation ( hematology , general biochemistry , coagulation , ECG , urinalysis ) 1 . Pregnant breastfeed 2 . Absolute neutrophil count ( ANC ) &lt; 1.8 x 109/L screening ( repeat perform ) 3 . History significant hypersensitivity deferiprone relate product ( include excipients formulation ) well severe hypersensitivity reaction ( angioedema ) drug 4 . History presence gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug know potentiate predispose undesired effect 5 . Presence significant cardiovascular , pulmonary , hematologic , neurological , psychiatric , endocrine , immunologic dermatologic disease 6 . Suicidal tendency , history seizure , history head trauma coma craniotomy/trepanation , state confusion , clinically relevant psychiatric disease 7 . Presence outofrange cardiac interval ( PR &lt; 110 msec , PR &gt; 220 msec , QRS &lt; 60 msec , QRS &gt; 119 msec QTcF &gt; 450 msec male &gt; 460 msec female ) screen ECG clinically significant ECG abnormalities 8 . Maintenance therapy drug significant history drug dependency alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) 9 . Any clinically significant illness previous 28 day Day 1 study 10 . Use enzymemodifying drug , include strong inhibitor cytochrome P450 ( CYP ) enzymes ( cimetidine , fluoxetine , quinidine , erythromycin , ciprofloxacin , fluconazole , ketoconazole , diltiazem HIV antiviral ) strong inducer CYP enzyme ( barbiturate , carbamazepine , glucocorticoid , phenytoin , rifampin St John 's Wort ) , previous 28 day Day 1 study 11 . Any history tuberculosis and/or prophylaxis tuberculosis 12 . Serum ferritin value normal limit reference laboratory screen 13 . Positive urine screen alcohol and/or drug abuse 14 . Positive result HIV Ag/Ab Combo , Hepatitis B surface Antigen ( HBsAG ( B ) ( hepatitis B ) ) antiHepatitis C Virus ( HCV ( C ) ) test 15 . Positive result serum pregnancy test 16 . Receipt investigational product another clinical trial previous 28 day Day 1 study 17 . Donation 50 mL blood previous 28 day Day 1 study donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day Day 1 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>deferiprone</keyword>
	<keyword>deferiprone extend release formulation</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>